Abbott India, Cipla, Biocon may get some relief from the GST Council: Exclusive
Sources further said that the GST council nominated fitment committee is likely to reduce GST on cancer drugs like Trastuzumab Deruxtecan, Osimertinib, Durvalumab to 5% from the current levels of 12%.
CIPLA
BIOCON
General
Markets